For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
PharmAthene disclosed in its 2Q14 earnings that it reduced R&D headcount by 11, or 33% of its technical staff. The cuts were in response to an April notice from HHS’s Biomedical Advanced Research and Development...
PharmAthene said FDA placed its SparVax program on clinical hold. According to the company, the agency said PharmAthene will receive a letter providing details of the basis for the hold within 30 days. A Phase...
In rabbits, doses of intramuscular SparVax containing 0.1, 0.3 and 1 µg of recombinant protective antigen (rPA) given on days 0 and 28 each significantly increased survival rates following challenge with Bacillus anthracis spores on...
Biodefense company PharmAthene and antibody company Theraclone will merge in a stock deal, which is expected to close next quarter. PharmAthene will be the surviving entity. Theraclone will own 50% of the surviving entity. Theraclone's...
PharmAthene said FDA lifted a clinical hold on the company's SparVax anthrax vaccine program after reviewing additional stability data submitted by the company. FDA placed the program on clinical hold in August 2012 prior to...
FDA placed the SparVax anthrax vaccine program on clinical hold. PharmAthene expects to receive a letter within 30 days providing details on the basis for the hold. PharmAthene said it "suspects" what the reason might...
Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) fell $0.39 (14%) to $2.41 on Wednesday after the U.K.'s NICE issued draft guidance recommending against the use of Iluvien fluocinolone acetonide intravitreal implant to treat chronic diabetic macular...
PharmAthene Inc. (NYSE-M:PIP) fell $0.19 (13%) to $1.27 on Friday after FDA placed the company's SparVax anthrax vaccine program on clinical hold. PharmAthene expects to receive a letter within 30 days providing details on the...
